Articles by Kaitlyn D’Onofrio
Dr. Tagawa explains the benefits and roadblocks of PSMA-targeting in prostate cancer treatment.
Andrei Iagaru, MD, Professor of Radiology – Nuclear Medicine and the Chief of the Division of Nuclear Medicine and ...
Jacob Berchuck, MD, discusses clinical considerations for the management of androgen indifferent prostate cancer.
Jacob Berchuck, MD, discusses clinical considerations for the management of androgen indifferent prostate cancer.
Researchers recently developed a gene signature to identify younger men with prostate cancer who were at risk for metastasis.
PSA levels at or near the time of death in patients with mCRPC can show patterns in disease characteristics and outcomes.
Dr. Neeraj Agarwal discusses DNA damage repair gene mutations in paired primary and metastatic prostate cancer samples.
Castration-resistant prostate cancer with high Gleason score, PSA may benefit from added 18F-FDG PET/CT and 68Ga-PSMA PET/CT.
The relationship between high CIN and NE CTC phenotype and poorer survival in mCRPC treated with abiraterone or enzalutamide.
Dr. Iagaru discusses current trials for PSMA and GRPR, the prostate cancer treatment pipeline, and Axumin versus PSMA.
The transparent, robust, and validated model will help with patient conversations and clinical trial designs.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.